2023-07-28 06:49:12
Severance Hospital’s endocrinology department professors Cha Bong-soo, Lee Yong-ho, and Lee Min-young, and hepatobiliary and pancreas surgery professor Han Dae-hoon’s research team announced on the 28th that ‘SGLT-2 inhibitor’, which is prescribed to diabetic patients to drop blood sugar, reduces glucose accumulation in hepatocytes and alleviates hepatitis.
The results of this study were published in the latest issue of Metabolism: Clinical and Experimental (IF 9.8), an international journal in the field of endocrine metabolism.
According to the hospital, the research team analyzed the liver tissues of 29 patients with non-alcoholic fatty liver disease and 15 patients without non-alcoholic fatty liver disease among patients who underwent liver resection or cholecystectomy for liver cancer or cholecystitis at Severance Hospital for 4 years from 2015. I did. As a result, it was confirmed that SGLT-2, a protein that transports sugar into cells, and intracellular sugar-binding proteins increased in the liver with non-alcoholic steatohepatitis.
Accordingly, the research team hypothesized that the SGLT-2 inhibitor, a diabetes drug that lowers blood sugar, would alleviate nonalcoholic steatohepatitis by reducing excessive sugar intake into hepatocytes, and observed mice that induced nonalcoholic steatohepatitis. It was confirmed to show the same protein change pattern as in patients with alcoholic steatohepatitis.
In addition, the autophagy of hepatocytes, which clean diseased tissues and wastes on their own, decreased in mice and the range of liver inflammation widened. I figured it out because of the lack of functionality.
Afterwards, when SGLT-2 inhibitor was administered, the amount of SGLT-2 protein expression and sugar-linked protein decreased in the liver of mice, as well as the autophagy of hepatocytes was restored and the inflammatory response was alleviated. It was explained that the symptoms of non-alcoholic steatohepatitis were alleviated.
Professor Bong-Soo Cha said, “This study is meaningful as it is the first study to suggest medical evidence and mechanism that SGLT-2 inhibitors for diabetes treatment alleviate the symptoms of non-alcoholic steatohepatitis.” It is expected to improve the prognosis of non-alcoholic steatohepatitis, which is on the rise, and prevent deterioration to liver cirrhosis and liver cancer.”
© Pax Economy TV Unauthorized reproduction and redistribution prohibited
1690527990
#Severance #Hospital #Diabetes #treatment #alleviate #symptoms #steatohepatitis
